Bevacizumab-induced Diffusion-restricted Lesions in Malignant Glioma Patients

Overview

Journal J Neurooncol

Publisher Springer

Date 2009 Dec 26

PMID 20035366

Citations 61

Authors

Johannes Rieger

Oliver Bahr

Klaus Muller

Kea Franz

Joachim Steinbach

Elke Hattingen

Affiliations

Soon will be listed here.

Abstract

Bevacizumab is an anti-vascular endothelial growth factor (VEGF) antibody with activity against recurrent malignant glioma inducing high rates of objective responses as assessed by magnetic resonance imaging (MRI). However, the mechanisms of the anti-tumor action of bevacizumab are controversial. In particular, it is unclear whether and when bevacizumab induces hypoxia in gliomas. Vascular normalization with hyperperfusion and enhanced oxygen delivery to the tumor has been suggested as an alternative mechanism. We analyzed diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) maps in 18 consecutive patients with recurrent malignant glioma before and after exposure to bevacizumab. Stroke-like lesions with diffusion restriction on DWI and corresponding ADC decrease were induced by bevacizumab within the previously enhancing tumor area in 13 of 18 patients. These lesions were detectable as early as 4 weeks after initiation of therapy and were maintained for up to 80 weeks. In one patient, an ADC-decreased lesion was biopsied, and histology showed atypical necrosis and nuclear hypoxia-inducible factor 1alpha upregulation but no tumor recurrence. Normalized regional cerebral blood flow (rCBF) and regional cerebral blood volume (rCBV) were analyzed in selected patients. Both parameters were decreased in responders with diffusion-restricted lesions. Within the tumor bed, bevacizumab induces diffusion-restricted lesions in the presence of reduced rCBF and rCBV. The cause of these alterations is unclear but may involve atypical necrosis and chronic hypoxia.

Citing Articles

Mechanism and significance of diffusion restriction followed by calcification in high-grade glioma treated with bevacizumab.

Hosoya T, Kambe A, Kesumayadi I, Makishima K, Sueyoshi S, Sakamoto M Sci Rep. 2024; 14(1):26419.

PMID: 39488647 PMC: 11531518. DOI: 10.1038/s41598-024-78226-4.

The Use of Apparent Diffusion Coefficient Values for Differentiating Bevacizumab-Related Cytotoxicity from Tumor Recurrence and Radiation Necrosis in Glioblastoma.

Khalaj K, Jacobs M, Zhu J, Esquenazi Y, Hsu S, Tandon N Cancers (Basel). 2024; 16(13).

PMID: 39001500 PMC: 11240552. DOI: 10.3390/cancers16132440.

The utility of arterial spin labeling imaging for predicting prognosis after a recurrence of high-grade glioma in patients under bevacizumab treatment.

Kambe A, Kitao S, Ochiai R, Hosoya T, Fujii S, Kurosaki M J Neurooncol. 2024; 166(1):175-183.

PMID: 38165552 DOI: 10.1007/s11060-023-04550-w.

Advanced Magnetic Resonance Imaging in the Evaluation of Treated Glioblastoma: A Pictorial Essay.

Martucci M, Russo R, Giordano C, Schiarelli C, DApolito G, Tuzza L Cancers (Basel). 2023; 15(15).

PMID: 37568606 PMC: 10417432. DOI: 10.3390/cancers15153790.

The relationship between radiation dose and bevacizumab-related imaging abnormality in patients with brain tumors: A voxel-wise normal tissue complication probability (NTCP) analysis.

Salans M, Houri J, Karunamuni R, Hopper A, Delfanti R, Seibert T PLoS One. 2023; 18(2):e0279812.

PMID: 36800342 PMC: 9937457. DOI: 10.1371/journal.pone.0279812.

References

Fischer I, Cunliffe C, Bollo R, Raza S, Monoky D, Chiriboga L . High-grade glioma before and after treatment with radiation and Avastin: initial observations. Neuro Oncol. 2008; 10(5):700-8. PMC: 2666246. DOI: 10.1215/15228517-2008-042. View

Friedman H, Prados M, Wen P, Mikkelsen T, Schiff D, Abrey L . Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27(28):4733-40. DOI: 10.1200/JCO.2008.19.8721. View

Vredenburgh J, Desjardins A, Herndon 2nd J, Marcello J, Reardon D, Quinn J . Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007; 25(30):4722-9. DOI: 10.1200/JCO.2007.12.2440. View

Winkler F, Kozin S, Tong R, Chae S, Booth M, Garkavtsev I . Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 2004; 6(6):553-63. DOI: 10.1016/j.ccr.2004.10.011. View

Castillo M, Smith J, Kwock L, Wilber K . Apparent diffusion coefficients in the evaluation of high-grade cerebral gliomas. AJNR Am J Neuroradiol. 2001; 22(1):60-4. PMC: 7975568. View

Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F . Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009; 15(3):220-31. PMC: 2874829. DOI: 10.1016/j.ccr.2009.01.027. View

Ostergaard L, Weisskoff R, Chesler D, Gyldensted C, Rosen B . High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: Mathematical approach and statistical analysis. Magn Reson Med. 1996; 36(5):715-25. DOI: 10.1002/mrm.1910360510. View

Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio P . Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell. 2003; 3(4):347-61. DOI: 10.1016/s1535-6108(03)00085-0. View

Zheng X, Jiang F, Katakowski M, Kalkanis S, Hong X, Zhang X . Inhibition of ADAM17 reduces hypoxia-induced brain tumor cell invasiveness. Cancer Sci. 2007; 98(5):674-84. PMC: 11158419. DOI: 10.1111/j.1349-7006.2007.00440.x. View

10.

Lee C, Heijn M, Di Tomaso E, Ancukiewicz M, Koike C, Park K . Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res. 2000; 60(19):5565-70. View

11.

Kamoun W, Ley C, Farrar C, Duyverman A, Lahdenranta J, Lacorre D . Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol. 2009; 27(15):2542-52. PMC: 2739611. DOI: 10.1200/JCO.2008.19.9356. View

12.

Erber R, Thurnher A, Katsen A, Groth G, Kerger H, Hammes H . Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 2003; 18(2):338-40. DOI: 10.1096/fj.03-0271fje. View

13.

Batchelor T, Sorensen A, Tomaso E, Zhang W, Duda D, Cohen K . AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007; 11(1):83-95. PMC: 2748664. DOI: 10.1016/j.ccr.2006.11.021. View

14.

Macdonald D, Cascino T, Schold Jr S, Cairncross J . Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990; 8(7):1277-80. DOI: 10.1200/JCO.1990.8.7.1277. View

15.

Jain R . Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005; 307(5706):58-62. DOI: 10.1126/science.1104819. View

16.

Sundgren P, Fan X, Weybright P, Welsh R, Carlos R, Petrou M . Differentiation of recurrent brain tumor versus radiation injury using diffusion tensor imaging in patients with new contrast-enhancing lesions. Magn Reson Imaging. 2006; 24(9):1131-42. DOI: 10.1016/j.mri.2006.07.008. View

17.

Server A, Kulle B, Maehlen J, Josefsen R, Schellhorn T, Kumar T . Quantitative apparent diffusion coefficients in the characterization of brain tumors and associated peritumoral edema. Acta Radiol. 2009; 50(6):682-9. DOI: 10.1080/02841850902933123. View

18.

Kreisl T, Kim L, Moore K, Duic P, Royce C, Stroud I . Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2008; 27(5):740-5. PMC: 2645088. DOI: 10.1200/JCO.2008.16.3055. View

19.

Ronellenfitsch M, Brucker D, Burger M, Wolking S, Tritschler F, Rieger J . Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death. Brain. 2009; 132(Pt 6):1509-22. DOI: 10.1093/brain/awp093. View

20.

Wick A, Felsberg J, Steinbach J, Herrlinger U, Platten M, Blaschke B . Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol. 2007; 25(22):3357-61. DOI: 10.1200/JCO.2007.10.7722. View